Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TJ0113 in Sarcopenia
NCT07620938Phase 2Recruiting
- Sponsor
- Phecda Medicine
- Start
- Jun 2026
- Primary completion
- Aug 2027
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of TJ0113 in Sarcopenia (4 arms), sponsored by Phecda Medicine. Primary endpoint: Change from baseline in gait speed on the 400-meter Walk Test at 26 weeks. Started Jun 2026; status: recruiting.
02
Drugs
TJ0113
03
Conditions
Sarcopenia
Beyond the preview
Go deeper on NCT07620938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07620938.